United Therapeutics Co. (UTHR) Shares Bought by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp boosted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,399 shares of the biotechnology company’s stock after purchasing an additional 1,124 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned about 0.20% of United Therapeutics worth $10,359,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of the stock. HPM Partners LLC boosted its position in United Therapeutics by 0.8% during the second quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock valued at $257,000 after purchasing an additional 15 shares in the last quarter. First Allied Advisory Services Inc. boosted its position in United Therapeutics by 0.4% during the second quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock valued at $598,000 after purchasing an additional 19 shares in the last quarter. Synovus Financial Corp boosted its position in United Therapeutics by 1.2% during the second quarter. Synovus Financial Corp now owns 5,639 shares of the biotechnology company’s stock valued at $731,000 after purchasing an additional 69 shares in the last quarter. Ifrah Financial Services Inc. raised its stake in United Therapeutics by 1.7% in the second quarter. Ifrah Financial Services Inc. now owns 4,437 shares of the biotechnology company’s stock valued at $576,000 after buying an additional 76 shares during the last quarter. Finally, Alps Advisors Inc. raised its stake in United Therapeutics by 2.3% in the second quarter. Alps Advisors Inc. now owns 3,827 shares of the biotechnology company’s stock valued at $496,000 after buying an additional 86 shares during the last quarter. 99.99% of the stock is currently owned by institutional investors.

Shares of United Therapeutics Co. (NASDAQ:UTHR) traded up $3.99 during trading hours on Tuesday, hitting $151.94. The stock had a trading volume of 441,820 shares, compared to its average volume of 335,600. United Therapeutics Co. has a 1 year low of $112.01 and a 1 year high of $169.89. The stock has a market capitalization of $6,393.07, a PE ratio of 13.40 and a beta of 1.41.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.01 by $2.26. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. The firm had revenue of $445.50 million during the quarter, compared to analysts’ expectations of $426.43 million. During the same period last year, the business posted $4.23 earnings per share. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. equities analysts expect that United Therapeutics Co. will post 12.96 earnings per share for the current fiscal year.

UTHR has been the subject of a number of research analyst reports. TheStreet upgraded United Therapeutics from a “c+” rating to a “b” rating in a research note on Friday, December 15th. ValuEngine upgraded United Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 30th. Oppenheimer reiterated a “buy” rating on shares of United Therapeutics in a research note on Friday, September 8th. Cowen reiterated a “hold” rating and issued a $129.00 price target on shares of United Therapeutics in a research note on Friday, October 27th. Finally, HC Wainwright reiterated a “hold” rating and issued a $95.00 price target on shares of United Therapeutics in a research note on Thursday, October 26th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $138.00.

In related news, CEO Martine A. Rothblatt sold 1,256 shares of United Therapeutics stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $122.98, for a total transaction of $154,462.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christopher Causey sold 580 shares of United Therapeutics stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $122.00, for a total value of $70,760.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,872 shares of company stock valued at $2,302,672. Company insiders own 7.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: “United Therapeutics Co. (UTHR) Shares Bought by Mitsubishi UFJ Trust & Banking Corp” was first published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.truebluetribune.com/2018/01/03/mitsubishi-ufj-trust-banking-corp-boosts-stake-in-united-therapeutics-co-uthr-2.html.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply